Up­dat­ed: In new speed bump for Hunt­ing­ton's, FDA paus­es PTC's PhII tri­al

PTC Ther­a­peu­tics has run in­to a road­block for its Hunt­ing­ton’s dis­ease pro­gram as the FDA flash­es the red light on a Phase II study.

The biotech — which is known for mar­ket­ing two drugs to treat Duchenne mus­cu­lar dy­s­tro­phy af­ter a con­tro­ver­sial de­vel­op­ment jour­ney — stopped short of say­ing the words “clin­i­cal hold” in a state­ment, and spent much of the up­date talk­ing about how it con­tin­ues to en­roll pa­tients in sev­er­al Eu­ro­pean coun­tries and Aus­tralia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER